|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cancer Registry and StatisticsCancer
Information Service, National Cancer Center. Japan:
|
|
3
|
Cassidy J, Clarke S, Díaz-Rubio E,
Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS,
Rivera F, et al: Randomized phase III study of capecitabine plus
oxaliplatin compared with fluorouracil/folinic acid plus
oxaliplatin as first-line therapy for metastatic colorectal cancer.
J Clin Oncol. 26:2006–2012. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Douillard JY, Siena S, Cassidy J,
Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham
D, Jassem J, et al: Randomized, phase III trial of panitumumab with
infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4)
versus FOLFOX4 alone as first-line treatment in patients with
previously untreated metastatic colorectal cancer: The PRIME study.
J Clin Oncol. 28:4697–4705. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Van Cutsem E, Köhne CH, Hitre E, Zaluski
J, Chien Chang CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G,
et al: Cetuximab and chemotherapy as initial treatment for
metastatic colorectal cancer. N Engl J Med. 360:1408–1417. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hazama S, Nakamura Y, Tanaka H, Hirakawa
K, Tahara K, Shimizu R, Ozasa H, Etoh R, Sugiura F, Okuno K, et al:
A phase II study of five peptides combination with
oxaliplatin-based chemotherapy as a first-line therapy for advanced
colorectal cancer (FXV study). J Transl Med. 12:1082014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kikuchi T, Daigo Y, Katagiri T, Tsunoda T,
Okada K, Kakiuchi S, Zembutsu H, Furukawa Y, Kawamura M, Kobayashi
K, et al: Expression profiles of non-small cell lung cancers on
cDNA microarrays: Identification of genes for prediction of
lymph-node metastasis and sensitivity to anti-cancer drugs.
Oncogene. 22:2192–2205. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shimokawa T, Matsushima S, Tsunoda T,
Tahara H, Nakamura Y and Furukawa Y: Identification of TOMM34,
which shows elevated expression in the majority of human colon
cancers, as a novel drug target. Int J Oncol. 29:381–386.
2006.PubMed/NCBI
|
|
9
|
Uchida N, Tsunoda T, Wada S, Furukawa Y,
Nakamura Y and Tahara H: Ring finger protein 43 as a new target for
cancer immunotherapy. Clin Cancer Res. 10:8577–8586. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Olofsson B, Korpelainen E, Pepper MS,
Mandriota SJ, Aase K, Kumar V, Gunji Y, Jeltsch MM, Shibuya M,
Alitalo K, et al: Vascular endothelial growth factor B (VEGF-B)
binds to VEGF receptor-1 and regulates plasminogen activator
activity in endothelial cells. Proc Natl Acad Sci USA.
95:11709–11714. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wada S, Tsunoda T, Baba T, Primus FJ,
Kuwano H, Shibuya M and Tahara H: Rationale for antiangiogenic
cancer therapy with vaccination using epitope peptides derived from
human vascular endothelial growth factor receptor 2. Cancer Res.
65:4939–4946. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nagorsen D and Thiel E: Clinical and
immunologic responses to active specific cancer vaccines in human
colorectal cancer. Clin Cancer Res. 12:3064–3069. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hazama S, Takenouchi H, Tsunedomi R, Iida
M, Suzuki N, Iizuka N, Inoue Y, Sakamoto K, Nakao M, Shindo Y, et
al: Predictive biomarkers for the outcome of vaccination of five
therapeutic epitope peptides for colorectal cancer. Anticancer Res.
34:4201–4205. 2014.PubMed/NCBI
|
|
14
|
Bacolod MD and Barany F: Molecular
profiling of colon tumors: The search for clinically relevant
biomarkers of progression, prognosis, therapeutics, and
predisposition. Ann Surg Oncol. 18:3694–3700. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Giessen-Jung C, Nagel D, Glas M, Spelsberg
F, Lau-Werner U, Modest DP, Schulz C, Heinemann V, Di Gioia D and
Stieber P: Preoperative serum markers for individual patient
prognosis in stage I–III colon cancer. Tumour Biol. 36:7897–7906.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ozawa T, Ishihara S, Kawai K, Nozawa H,
Yamaguchi H, Kitayama J and Watanabe T: Prognostic significance of
preoperative serum carbohydrate antigen 19-9 in patients with stage
IV colorectal cancer. Clin Colorectal Cancer. 15:e157–e163. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kijima T, Hazama S, Tsunedomi R, Tanaka H,
Takenouchi H, Kanekiyo S, Inoue Y, Nakashima M, Iida M, Sakamoto K,
et al: MicroRNA-6826 and −6875 in plasma are valuable non invasive
biomarkers that predict the efficacy of vaccine treatment against
metastatic colorectal cancer. Oncol Rep. 37:23–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kitahara M, Hazama S, Tsunedomi R,
Takenouchi H, Kanekiyo S, Inoue Y, Nakajima M, Tomochika S,
Tokuhisa Y, Iida M, et al: Prediction of the efficacy of
immunotherapy by measuring the integrity of cell-free DNA in plasma
in colorectal cancer. Cancer Sci. 107:1825–1829. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shindo Y, Hazama S, Suzuki N, Iguchi H,
Uesugi K, Tanaka H, Aruga A, Hatori T, Ishizaki H, Umeda Y, et al:
Predictive biomarkers for the efficacy of peptide vaccine
treatment: based on the results of a phase II study on advanced
pancreatic cancer. J Exp Clin Cancer Res. 36:362017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Noguchi M, Mine T, Komatsu N, Suekane S,
Moriya F, Matsuoka K, Yutani S, Shichijo S, Yamada A, Toh U, et al:
Assessment of immunological biomarkers in patients with advanced
cancer treated by personalized peptide vaccination. Cancer Biol
Ther. 10:1266–1279. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mine T, Sato Y, Noguchi M, Sasatomi T,
Gouhara R, Tsuda N, Tanaka S, Shomura H, Katagiri K, Rikimaru T, et
al: Humoral responses to peptides correlate with overall survival
in advanced cancer patients vaccinated with peptides based on
pre-existing, peptide-specific cellular responses. Clin Cancer Res.
10:929–937. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Suda T, Tsunoda T, Daigo Y, Nakamura Y and
Tahara H: Identification of human leukocyte antigen-A24-restricted
epitope peptides derived from gene products upregulated in lung and
esophageal cancers as novel targets for immunotherapy. Cancer Sci.
98:1803–1808. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ishizaki H, Tsunoda T, Wada S, Yamauchi M,
Shibuya M and Tahara H: Inhibition of tumor growth with
antiangiogenic cancer vaccine using epitope peptides derived from
human vascular endothelial growth factor receptor 1. Clin Cancer
Res. 12:5841–5849. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kato T, Muro K, Yamaguchi K, Bando H,
Hazama S, Amagai K, Baba H, Denda T, Shi X, Fukase K, et al:
Cediranib in combination with mFOLFOX6 in Japanese patients with
metastatic colorectal cancer: Results from the randomised phase II
part of a phase I/II study. Ann Oncol. 23:933–941. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Saltz LB, Clarke S, Díaz-Rubio E,
Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS,
Rivera F, et al: Bevacizumab in combination with oxaliplatin-based
chemotherapy as first-line therapy in metastatic colorectal cancer:
A randomized phase III study. J Clin Oncol. 26:2013–2019. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Suzuki N, Hazama S, Ueno T, Matsui H,
Shindo Y, Iida M, Yoshimura K, Yoshino S, Takeda K and Oka M: A
phase I clinical trial of vaccination with KIF20A-derived peptide
in combination with gemcitabine for patients with advanced
pancreatic cancer. J Immunother. 37:36–42. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hazama S, Nakamura Y, Takenouchi H, Suzuki
N, Tsunedomi R, Inoue Y, Tokuhisa Y, Iizuka N, Yoshino S, Takeda K,
et al: A phase I study of combination vaccine treatment of five
therapeutic epitope-peptides for metastatic colorectal cancer;
safety, immunological response, and clinical outcome. J Transl Med.
12:632014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kono K, Iinuma H, Akutsu Y, Tanaka H,
Hayashi N, Uchikado Y, Noguchi T, Fujii H, Okinaka K, Fukushima R,
et al: Multicenter, phase II clinical trial of cancer vaccination
for advanced esophageal cancer with three peptides derived from
novel cancer-testis antigens. J Transl Med. 10:1412012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Komatsu N, Shichijo S, Nakagawa M and Itoh
K: New multiplexed flow cytometric assay to measure anti-peptide
antibody: A novel tool for monitoring immune responses to peptides
used for immunization. Scand J Clin Lab Invest. 64:535–545. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zeh HJ III, Leder GH, Lotze MT, Salter RD,
Tector M, Stuber G, Modrow S and Storkus WJ: Flow-cytometric
determination of peptide-class I complex formation. Identification
of p53 peptides that bind to HLA-A2. Hum Immunol. 39:79–86. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tahara T, Yang SY, Khan R, Abish S,
Hämmerling GJ and Hämmerling U: HLA antibody responses in HLA class
I transgenic mice. Immunogenetics. 32:351–360. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Udaka K, Wiesmüller KH, Kienle S, Jung G,
Tamamura H, Yamagishi H, Okumura K, Walden P, Suto T and Kawasaki
T: An automated prediction of MHC class I-binding peptides based on
positional scanning with peptide libraries. Immunogenetics.
51:816–828. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Novellino L, Castelli C and Parmiani G: A
listing of human tumor antigens recognized by T cells: March 2004
update. Cancer Immunol Immunother. 54:187–207. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rosenberg SA: A new era for cancer
immunotherapy based on the genes that encode cancer antigens.
Immunity. 10:281–287. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rosenberg SA, Yang JC and Restifo NP:
Cancer immunotherapy: Moving beyond current vaccines. Nat Med.
10:909–915. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Maiers M, Gragert L and Klitz W:
High-resolution HLA alleles and haplotypes in the United States
population. Hum Immunol. 68:779–788. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bequet-Romero M, Morera Y, Ayala-Ávila M,
Ancizar J, Soria Y, Blanco A, Suárez-Alba J and Gavilondo JV:
CIGB-247: A VEGF-based therapeutic vaccine that reduces
experimental and spontaneous lung metastasis of C57Bl/6 and BALB/c
mouse tumors. Vaccine. 30:1790–1799. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zeng J, Cai S, Yi Y, He Y, Wang Z, Jiang
G, Li X and Du J: Prevention of spontaneous tumor development in a
ret transgenic mouse model by ret peptide vaccination with
indoleamine 2,3-dioxygenase inhibitor 1-methyl tryptophan. Cancer
Res. 69:3963–3970. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Itoh K and Yamada A: Personalized peptide
vaccines: A new therapeutic modality for cancer. Cancer Sci.
97:970–976. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mine T, Gouhara R, Hida N, Imai N, Azuma
K, Rikimaru T, Katagiri K, Nishikori M, Sukehiro A, Nakagawa M, et
al: Immunological evaluation of CTL precursor-oriented vaccines for
advanced lung cancer patients. Cancer Sci. 94:548–556. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sato Y, Fujiwara T, Mine T, Shomura H,
Homma S, Maeda Y, Tokunaga N, Ikeda Y, Ishihara Y, Yamada A, et al:
Immunological evaluation of personalized peptide vaccination in
combination with a 5-fluorouracil derivative (TS-1) for advanced
gastric or colorectal carcinoma patients. Cancer Sci. 98:1113–1119.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Antony PA, Piccirillo CA, Akpinarli A,
Finkelstein SE, Speiss PJ, Surman DR, Palmer DC, Chan CC, Klebanoff
CA, Overwijk WW, et al: CD8+ T cell immunity against a
tumor/self-antigen is augmented by CD4+ T helper cells
and hindered by naturally occurring T regulatory cells. J Immunol.
174:2591–2601. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Itoh K, Yamada A, Mine T and Noguchi M:
Recent advances in cancer vaccines: An overview. Jpn J Clin Oncol.
39:73–80. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Noguchi M, Yao A, Harada M, Nakashima O,
Komohara Y, Yamada S, Itoh K and Matsuoka K: Immunological
evaluation of neoadjuvant peptide vaccination before radical
prostatectomy for patients with localized prostate cancer.
Prostate. 67:933–942. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lanitis E, Irving M and Coukos G:
Targeting the tumor vasculature to enhance T cell activity. Curr
Opin Immunol. 33:55–63. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang L, Conejo-Garcia JR, Katsaros D,
Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H,
Schlienger K, Liebman MN, et al: Intratumoral T cells, recurrence,
and survival in epithelial ovarian cancer. N Engl J Med.
348:203–213. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Gabrilovich DI, Ostrand-Rosenberg S and
Bronte V: Coordinated regulation of myeloid cells by tumours. Nat
Rev Immunol. 12:253–268. 2012. View Article : Google Scholar : PubMed/NCBI
|
